{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:45:42Z","timestamp":1792431942567,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770599"],"award-info":[{"award-number":["81770599"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900550"],"award-info":[{"award-number":["81900550"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970526"],"award-info":[{"award-number":["81970526"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100639"],"award-info":[{"award-number":["82100639"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejphar.2021.174713","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T20:03:29Z","timestamp":1640030609000},"page":"174713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction"],"prefix":"10.1016","volume":"915","author":[{"given":"Lei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6311-1811","authenticated-orcid":false,"given":"Zhifeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7123-1867","authenticated-orcid":false,"given":"Guangbo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolou","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-7476","authenticated-orcid":false,"given":"Meng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174713_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1756-3305-6-199","article-title":"Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection","volume":"6","author":"Attia","year":"2013","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.ejphar.2021.174713_bib2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0016-5085(00)70368-4","article-title":"Angiotensin II induces contraction and proliferation of human hepatic stellate cells","volume":"118","author":"Bataller","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2021.174713_bib3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2021.174713_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jhep.2015.01.003","article-title":"Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments","volume":"62","author":"Bosch","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2021.174713_bib5","doi-asserted-by":"crossref","first-page":"E4161","DOI":"10.3390\/ijms20174161","article-title":"Glucobrassicin metabolites ameliorate the development of portal hypertension and cirrhosis in bile duct-ligated rats","volume":"20","author":"Chang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2021.174713_bib6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1152\/ajpgi.00162.2009","article-title":"Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C","volume":"297","author":"Colmenero","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejphar.2021.174713_bib7","first-page":"575","article-title":"The effect of the angiotensin II receptor, type 1 receptor antagonists, losartan and telmisartan, on thioacetamide-induced liver fibrosis in rats","volume":"67","author":"Czechowska","year":"2016","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174713_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226185","article-title":"In-depth hepatoprotective mechanistic study of Phyllanthus niruri: in vitro and in vivo studies and its chemical characterization","volume":"15","author":"Ezzat","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2021.174713_bib9","first-page":"918","article-title":"MicroRNA-146b regulates hepatic stellate cell activation via targeting of KLF4","volume":"15","author":"Ge","year":"2016","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.ejphar.2021.174713_bib10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/ki.2015.178","article-title":"Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria","volume":"88","author":"Hayashi","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2021.174713_bib11","first-page":"587140","article-title":"Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: fatty liver protection trial by telmisartan or losartan study (FANTASY)","author":"Hirata","year":"2013","journal-title":"Internet J. Endocrinol."},{"key":"10.1016\/j.ejphar.2021.174713_bib12","first-page":"1261","article-title":"Antifibrotic action of telmisartan in experimental carbon tetrachloride-induced liver fibrosis in Wistar rats","volume":"57","author":"Ionic\u0103","year":"2016","journal-title":"Rom. J. Morphol. Embryol."},{"key":"10.1016\/j.ejphar.2021.174713_bib13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jhep.2014.05.047","article-title":"Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions","volume":"61","author":"Iwakiri","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2021.174713_bib14","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2014.01.024","article-title":"Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013","volume":"60","author":"Jalan","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2021.174713_bib15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.bbrc.2007.10.083","article-title":"Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet","volume":"364","author":"Jin","year":"2007","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.ejphar.2021.174713_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3389\/fphys.2015.00327","article-title":"The role of kr\u00fcppel-like factor 4 in renal fibrosis","volume":"6","author":"Ke","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2021.174713_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3389\/fcimb.2017.00443","article-title":"Corilagin counteracts IL-13R\u03b11 signaling pathway in macrophages to mitigate schistosome egg-induced hepatic fibrosis","volume":"7","author":"Li","year":"2017","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.ejphar.2021.174713_bib18","doi-asserted-by":"crossref","first-page":"15847","DOI":"10.1038\/s41598-017-14602-7","article-title":"Kr\u00fcpple-like-factor 4 attenuates lung fibrosis via inhibiting epithelial-mesenchymal transition","volume":"7","author":"Lin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2021.174713_bib19","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10620-012-2499-3","article-title":"Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-\/- mouse model","volume":"58","author":"Mende","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejphar.2021.174713_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1291\/hypres.29.567","article-title":"Renal and vascular protective effects of telmisartan in patients with essential hypertension","volume":"29","author":"Morimoto","year":"2006","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2021.174713_bib21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/MOG.0b013e3283460c7d","article-title":"Complications and outcomes in chronic liver disease","volume":"27","author":"Rahimi","year":"2011","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.ejphar.2021.174713_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1472-8206.2008.00611.x","article-title":"Curcumin prevents and reverses cirrhosis induced by bile duct obstruction or CCl4 in rats: role of TGF-beta modulation and oxidative stress","volume":"22","author":"Reyes-Gordillo","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174713_bib23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1478-3231.2010.02264.x","article-title":"The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis","volume":"30","author":"Schuppan","year":"2010","journal-title":"Liver Int."},{"key":"10.1016\/j.ejphar.2021.174713_bib24","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1111\/liv.12795","article-title":"Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites","volume":"35","author":"Schwabl","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.ejphar.2021.174713_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Sepanlou","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2021.174713_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhep.2010.03.013","article-title":"Renin\u2013angiotensin\u2013aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis","volume":"53","author":"Tandon","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2021.174713_bib27","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1517\/14656566.8.14.2225","article-title":"Effect of angiotensin-converting enzyme insertion\/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension","volume":"8","author":"Tziakas","year":"2007","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2021.174713_bib28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbrc.2009.12.002","article-title":"Defining the regulation of KLF4 expression and its downstream transcriptional targets in vascular endothelial cells","volume":"391","author":"Villarreal","year":"2010","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.ejphar.2021.174713_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.arr.2017.11.002","article-title":"FOXO1\/3: potential suppressors of fibrosis","volume":"41","author":"Xin","year":"2018","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejphar.2021.174713_bib30","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/aps.2012.115","article-title":"Telmisartan attenuates hepatic fibrosis in bile duct-ligated rats","volume":"33","author":"Yi","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2021.174713_bib31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00018-012-1046-x","article-title":"Peroxisome proliferator-activated receptor-\u03b3 as a therapeutic target for hepatic fibrosis: from bench to bedside","volume":"70","author":"Zhang","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2021.174713_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/hr.2013.119","article-title":"Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-\u03b21\/Smad signal pathway","volume":"37","author":"Zhang","year":"2014","journal-title":"Hypertens. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921008694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921008694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:58:33Z","timestamp":1757977113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921008694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":32,"alternative-id":["S0014299921008694"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174713","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174713","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"174713"}}